Literature DB >> 16122570

Cognition in schizophrenia: impairments, determinants, and functional importance.

Christopher R Bowie1, Philip D Harvey.   

Abstract

Recent findings support and add to earlier findings of cognitive dysfunction in schizophrenia. Deficits across neurocognitive domains such as attention, working memory, language skills, and executive functioning tend to be moderate, with the most pronounced deficits found in verbal learning and memory. All these neurocognitive domains are related to adaptive and social skills, with executive functions and verbal learning and memory showing more variance across more domains than other neuro-cognitive variables. Negative symptoms and neurocognitive domains, although correlated, are distinct and have differential pathways of change with treatment. General psychopathology symptoms, such as depression and anxiety, may become important treatment targets as strategies are developed for translating cognitive enhancement to real-world functional performance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16122570     DOI: 10.1016/j.psc.2005.05.004

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  68 in total

1.  Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.

Authors:  Mario Pfammatter; Ulrich Martin Junghan; Hans Dieter Brenner
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

2.  Gestalt perception and local-global processing in high-functioning autism.

Authors:  Sven Bölte; Martin Holtmann; Fritz Poustka; Armin Scheurich; Lutz Schmidt
Journal:  J Autism Dev Disord       Date:  2006-10-07

3.  A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia.

Authors:  Peter D Alexander; Kristina M Gicas; Alex Cheng; Donna J Lang; Ric M Procyshyn; Alexandra T Vertinsky; William J Panenka; Allen E Thornton; Alexander Rauscher; Jamie Y X Wong; Tasha Chan; Andrea A Jones; F Vila-Rodriguez; William G Honer; Alasdair M Barr
Journal:  Psychopharmacology (Berl)       Date:  2019-06-22       Impact factor: 4.530

4.  Deficits in cue detection and intention retrieval underlie prospective memory impairment in schizophrenia.

Authors:  Steven Paul Woods; Elizabeth W Twamley; Matthew S Dawson; Jenille M Narvaez; Dilip V Jeste
Journal:  Schizophr Res       Date:  2006-12-15       Impact factor: 4.939

5.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

7.  Cognitive functioning and negative symptoms in first episode schizophrenia: different patterns of correlates.

Authors:  José Manuel Rodríguez-Sánchez; Benedicto Crespo-Facorro; César González-Blanch; Rocío Pérez-Iglesias; Mario Alvarez-Jiménez; Obdulia Martínez; José Luis Vázquez-Barquero
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia.

Authors:  Amresh K Shrivastava; Megan E Johnston
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

Review 9.  Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms.

Authors:  Ryan J Van Lieshout; Lakshmi P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2008-09       Impact factor: 6.186

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.